Impact of resection margin status on recurrence and survival in pancreatic cancer surgery.

Published on Jul 1, 2019in British Journal of Surgery5.676
· DOI :10.1002/BJS.11115
W. S. Tummers1
Estimated H-index: 1
(LEI: Leiden University),
Jesse V. Groen5
Estimated H-index: 5
(LEI: Leiden University)
+ 8 AuthorsRutger-Jan Swijnenburg25
Estimated H-index: 25
(LEI: Leiden University)
Sources
Abstract
Background: The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) is poor and selection of patients for surgery is challenging. This study examined the impact of a positive resection margin (R1) on locoregional recurrence (LRR) and overall survival (OS); and also aimed to identified tumour characteristics and/or technical factors associated with a positive resection margin in patients with PDAC. Methods: Patients scheduled for pancreatic resection for PDAC between 2006 and 2016 were identified from an institutional database. The effect of resection margin status, patient characteristics and tumour characteristics on LRR, distant metastasis and OS was assessed. Results: A total of 322 patients underwent pancreatectomy for PDAC. A positive resection (R1) margin was found in 129 patients (40·1 per cent); this was associated with decreased OS compared with that in patients with an R0 margin (median 15 (95 per cent c.i. 13 to 17) versus 22 months; P < 0·001). R1 status was associated with reduced time to LRR (median 16 versus 36 (not estimated, n.e.) months; P = 0·002). Disease recurrence patterns were similar in the R1 and R0 groups. Risk factors for early recurrence were tumour stage, positive lymph nodes (N1) and perineural invasion. Among 100 patients with N0 disease, R1 status was associated with shorter OS compared with R0 resection (median 17 (10 to 24) versus 45 (n.e.) months; P = 0·002), whereas R status was not related to OS in 222 patients with N1 disease (median 14 (12 to 16) versus 17 (15 to 19) months after R1 and R0 resection respectively; P = 0·068). Conclusion: Although pancreatic resection with a positive margin was associated with poor survival and early recurrence, particularly in patients with N1 disease, disease recurrence patterns were similar between R1 and R0 groups.
Figures & Tables
Download
📖 Papers frequently viewed together
20133.36Surgery
69 Citations
20193.36Surgery
20 Authors (Xu Feng Zhang, ..., Timothy M. Pawlik)
20 Citations
835 Citations
References42
Newest
#1Willemieke S. Tummers (Stanford University)H-Index: 12
#2Sarah E. Miller (Stanford University)H-Index: 8
Last. Eben L. Rosenthal (Stanford University)H-Index: 61
view all 18 authors...
Background Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imagi...
66 CitationsSource
#1Paula Ghaneh (University of Liverpool)H-Index: 62
#2Jörg KleeffH-Index: 94
Last. John P. NeoptolemosH-Index: 125
view all 32 authors...
Objective and Background:Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapies.Methods:Analyses were carried out to assess the association between clinical
104 CitationsSource
#1Arsen Osipov (Cedars-Sinai Medical Center)H-Index: 7
#2Nicholas N. Nissen (Cedars-Sinai Medical Center)H-Index: 26
Last. Richard Tuli (Cedars-Sinai Medical Center)H-Index: 28
view all 9 authors...
Purpose There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA.
19 CitationsSource
#1Daniel Ansari (Lund University)H-Index: 25
#2Monika Bauden (Lund University)H-Index: 13
Last. Roland Andersson (Lund University)H-Index: 79
view all 6 authors...
Background The size of pancreatic ductal adenocarcinoma (PDAC) at diagnosis is an indicator of outcome. Previous studies have focused mostly on patients with resectable disease. The aim of this study was to investigate the relationship between tumour size and risk of metastasis and death in a large PDAC cohort, including all stages. Methods Patients diagnosed with PDAC between 1988 and 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Tumour size was defi...
37 CitationsSource
#1M Elshaer (Broomfield Hospital)H-Index: 1
#2G Gravante (Leicester Royal Infirmary)H-Index: 1
Last. A Al-Bahrani (Watford General Hospital)H-Index: 1
view all 5 authors...
BACKGROUND Pancreatic ductal adenocarcinoma is the most common pancreatic cancer. Five-year overall survival is currently 3.3–6.0%. The aim of this review was to evaluate the prognostic value of lymph node ratio, number of positive nodes and total nodes examined on overall survival rate following pancreatic resection. MATERIALS AND METHODS A literature search was conducted of MEDLINE, EMBASE, the Cochrane Library and Central Register of Controlled Trials and the Cochrane Database of Systematic R...
37 CitationsSource
#1Scott W. Baldwin (Roswell Park Cancer Institute)H-Index: 1
#2Moshim Kukar (Roswell Park Cancer Institute)H-Index: 13
Last. Boris W. Kuvshinoff (Roswell Park Cancer Institute)H-Index: 24
view all 7 authors...
Background The purpose of this study was to determine the association of the extent of metastatic lymph node involvement with survival in pancreatic cancer.
12 CitationsSource
#1Eva VersteijneH-Index: 11
#2Casper H.J. van Eijck (EUR: Erasmus University Rotterdam)H-Index: 72
Last. Geertjan van TienhovenH-Index: 35
view all 23 authors...
Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2–7 % and has hardly improved over the last two decades. Approximately 15 % of all patients have resectable disease at diagnosis, and of those, only a subgroup has a resectable tumour at surgical exploration. Data from cohort studies have suggested that outcome can be improved by preoperative radiochemotherapy, bu...
98 CitationsSource
#1Cecilia G. Ethun (Emory University)H-Index: 19
#2David A. Kooby (Emory University)H-Index: 65
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a grim prognosis. Surgical resection offers the best chance for long-term survival, yet recurrence rates are high and outcomes are poor. The influence of margin status in PDAC is controversial, as conflicting data have been plagued by a lack of standardization in margin definitions, pathologic analysis, and reporting. Despite recent efforts, international consensus is still needed for this disease. J. Surg. Oncol. © 2015...
36 CitationsSource
#1Florian Gebauer (UHH: University of Hamburg)H-Index: 20
#2Michael Tachezy (UHH: University of Hamburg)H-Index: 22
Last. Maximilian Bockhorn (UHH: University of Hamburg)H-Index: 25
view all 7 authors...
Background and objectives The aim of this study was to assess the overall survival (OS) after R0/R1 resections in patients with pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head after implementation of a standardized histopathologic protocol (Leeds Pathology Protocol, LEEPP).
49 CitationsSource
#1Eugene PahkH-Index: 1
#2Raphael JesinH-Index: 1
Last. Jesse LachterH-Index: 17
view all 5 authors...
Objective To determine the time to recurrence of pancreatic adenocarcinoma of the head of the pancreas after curative resection at one tertiary-care Health Care Campus and to determine the factors that predict early recurrence. Methods Retrospective data was gathered from 64 consecutive pancreatic adenocarcinoma patients undergoing curative Whipple procedures from 2007-2011. Patients were divided into early recurrence, within 185 days, and late or no recurrence. Results Disease-free survival aft...
1 Citations
Cited By62
Newest
#1Jiawen YaoH-Index: 14
#2Yu Shi (PRC: China Medical University (PRC))H-Index: 2
view all 10 authors...
Abstract null null Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and carries a dismal prognosis of null null null ∼ null null 10% in five year survival rate. Surgery remains the best option of a potential cure for patients who are evaluated to be eligible for initial resection of PDAC. However, outcomes vary significantly even among the resected patients who were the same cancer stage and received similar treatments. Accurate quantitative preoperative prediction of pr...
Source
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite surgical and pharmacological progresses in the latest years. High potential for metastasis is the main cause of therapeutic failure in localized disease, highlighting the current limited knowledge of underneath pathological processes. However, nowadays the research is focusing on the search of personalized approach also in the adjuvant setting for PDAC, by implementing the use of biomarkers and investig...
Source
#1Artur Rebelo (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 3
#2Ulrich Ronellenfitsch (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 22
Last. Jörg Kleeff (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 94
view all 5 authors...
OBJECTIVE In this article, we outline the important features of pancreatic cancer surgery in cases with visceral artery encasement. BACKGROUND Despite recent advances in diagnosis and treatment, pancreatic cancer continues to have a poor prognosis. Due to its limited response to chemotherapies, radiation, or targeted therapies, surgery (in combination with adjuvant chemotherapy) is the only potential way to treat pancreatic cancer in a curative manner. As only about 20% of the patients have surg...
Source
#1Jakob Liermann (Heidelberg University)H-Index: 6
#2Edgar Ben-Josef (UPenn: University of Pennsylvania)H-Index: 18
Last. Patrick Naumann (Heidelberg University)H-Index: 10
view all 6 authors...
PURPOSE Data on management of locally recurrent pancreatic cancer (LRPC) after primary resection are limited. Recently, surprisingly high overall survival rates were reported after irradiation with carbon ions. Here, we report on our clinical experience using carbon ion radiotherapy as definitive treatment in LRPC at the Heidelberg Ion-Beam Therapy Center (HIT). METHODS Between 2015 and 2019, we treated 13 patients with LRPC with carbon ions with a median total dose of 48 Gy (RBE) in 12 fraction...
Source
#1John R. Bergquist (Mayo Clinic)H-Index: 12
#2Cornelius A. Thiels (Mayo Clinic)H-Index: 18
Last. Michael L. Kendrick (Mayo Clinic)H-Index: 58
view all 12 authors...
Introduction null Although surgical resection is necessary, it is not sufficient for long-term survival in pancreatic ductal adenocarcinoma (PDAC). We sought to evaluate survival after up-front surgery (UFS) in anatomically resectable PDAC in the context of three critical factors: (A) margin status; (B) CA19-9; and (C) receipt of adjuvant chemotherapy. null Methods null The National Cancer Data Base (2010-2015) was reviewed for clinically resectable (stage 0/I/II) PDAC patients. Surgical margins...
Source
view all 4 authors...
Purpose . To identify major factors affecting the overall survival (OS). To select the cohort of patients with the best prognosis. null null Materials and methods . A retrospective analysis included data of 268 patients, 128 men and 140 women, with median age of 59±10,53 (30 to 83) years. For multivariate analysis of survival, patients were selected who underwent pancreaticoduodenectomy (PD) for ductal adenocarcinoma of the pancreatic head. null null Results . Our study demonstrated that histolo...
Source
#1Rosa Klotz (Heidelberg University)H-Index: 3
#2Thilo Hackert (Heidelberg University)H-Index: 57
Last. Beat P. Müller-Stich (Heidelberg University)H-Index: 33
view all 14 authors...
Abstract null null Background null Surgical resection is the mainstay of potential cure for patients with pancreatic cancer, however, local recurrence is frequent. Previously, we have described an extended resection technique for pancreatoduodenectomy aiming at a radical resection of the nerve and lymphatic tissue between celiac artery, superior mesenteric artery and mesenteric-portal axis (TRIANGLE operation). Until now, data on postoperative outcome have not been reported, yet. null null null ...
Source
#2Etienne BuscailH-Index: 11
Last. Christophe LaurentH-Index: 68
view all 16 authors...
BACKGROUND Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison with upfront surgery (US). MATERIAL AND METHODS Between 2010 and 2017 patient records for all consecutive patients treated for BRPC according to NCCN 2017 were reviewed. The endpoints analysed were R0 rate, recurrence-free-survival (RFS) and overall survival (OS). RESULTS Seventy-nine pati...
Source
#1Michail N Mavros (University of Arkansas for Medical Sciences)
#1Michail N Mavros (University of Arkansas for Medical Sciences)
Last. Timothy M. Pawlik (The Ohio State University Wexner Medical Center)H-Index: 118
view all 6 authors...
Importance Adjuvant chemotherapy is the standard of care for resected pancreatic ductal adenocarcinoma (PDAC) based on level 1 evidence, but some studies suggest that a neoadjuvant approach (which is standard for borderline resectable PDAC) may be preferable for upfront resectable PDAC. An in-depth review was conducted of all randomized clinical trials that investigated neoadjuvant and adjuvant treatment of patients with resectable or resected PDAC, focusing on trial design, characteristics of e...
Source
#1Hongkai Zhuang (Peking Union Medical College)H-Index: 4
#2Zixuan Zhou (Peking Union Medical College)H-Index: 1
Last. Chuanzhao Zhang (Peking Union Medical College)H-Index: 4
view all 11 authors...
Background:The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) of pancreatic head remains poor, even after potentially curative R0 resection. The aim of this study was to develop...
Source